ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • biologic drugs and rheumatoid arthritis (RA)
  • biologic drugs and spondylarthritis
  • biologic drugs and tocilizumab
  • biologic drugs and tofacitinib
  • Biologic drugs and tuberculosis
  • biologic drugs and uveitis
  • biologic drugs and vasculitis
  • biologic refractory disease
  • biologic response modifiers
  • biologic response modifiers and anti-TNF therapy
  • biologic response modifiers and Biologics
  • biologic response modifiers and fungal infections
  • biologic response modifiers and health outcome
  • biologic response modifiers and infection
  • biologic response modifiers and methotrexate (MTX)
  • biologic response modifiers and occupational therapy
  • biologic response modifiers and patient questionnaires
  • Biologic response modifiers and pediatric rheumatology
  • biologic response modifiers and quality of life
  • biologic response modifiers and rheumatoid arthritis (RA)
  • biologic response modifiers and rituximab
  • biologic-experienced
  • Biologic-naive
  • Biological Age
  • Biological treatment
  • Biologicals
  • Biologics
  • Biologics and abatacept
  • Biologics and adult-onset Still's disease
  • Biologics and ankylosing spondylitis (AS)
  • Biologics and anti-CCP antibodies
  • Biologics and anti-TNF therapy
  • Biologics and back pain
  • Biologics and biosimilars
  • Biologics and cardiovascular disease
  • Biologics and cost containment
  • Biologics and Disease Activity
  • Biologics and DMARDs
  • Biologics and health care cost
  • Biologics and IL-6
  • Biologics and inflammatory arthritis
  • Biologics and infliximab
  • Biologics and Janus kinase (JAK)
  • Biologics and joint destruction
  • Biologics and meta-analysis
  • Biologics and patient-reported outcome measures
  • Biologics and Placebo
  • Biologics and polychondritis
  • Biologics and prognostic factors
  • Biologics and psoriatic arthritis
  • Biologics and registry
  • Biologics and rheumatoid arthritis (RA)
  • Biologics and safety
  • Biologics and spondylarthropathy
  • Biologics and surgery
  • Biologics and systemic lupus erythematosus (SLE)
  • Biologics and tocilizumab
  • Biologics and treatment
  • Biologics and use
  • Biologics and Work Disability
  • biomarker
  • biomarker and lymphoma
  • Biomarkers
  • biomarkers and anti-citrullinated protein/peptide antibodies (ACPA)
  • biomarkers and atherosclerosis
  • biomarkers and autoimmune diseases
  • biomarkers and BTK
  • biomarkers and canakinumab
  • biomarkers and cardiovascular disease
  • biomarkers and cartilage
  • biomarkers and central nervous system involvement
  • biomarkers and chemokines
  • biomarkers and cognitive dysfunction
  • biomarkers and collagen
  • biomarkers and complement
  • biomarkers and complex regional pain syndrome
  • Biomarkers and connective tissue diseases
  • biomarkers and cytokines
  • biomarkers and dermatomyositis
  • biomarkers and diagnosis
  • biomarkers and Disease Activity
  • biomarkers and disease-modifying antirheumatic drugs
  • Biomarkers and drug treatment
  • biomarkers and endothelial cells
  • Biomarkers and epidemiologic methods
  • Biomarkers and epigenetics
  • Biomarkers and fibromyalgia
  • biomarkers and fibrosis
  • biomarkers and flow cytometry
  • biomarkers and gastrointestinal complications
  • biomarkers and Gene Expression
  • biomarkers and giant cell arteritis
  • biomarkers and glomerulonephritis
  • biomarkers and glucocorticoids
  • biomarkers and histopathologic
  • biomarkers and IL-17
  • biomarkers and imaging techniques
  • biomarkers and immune activation
  • biomarkers and inflammation
  • biomarkers and inflammatory bowel disease (IBD)
  • biomarkers and innate immunity
  • biomarkers and insulin-like growth factor
  • biomarkers and interferons
  • biomarkers and joint damage
  • Biomarkers and juvenile arthritis
  • Biomarkers and juvenile idiopathic arthritis (JIA)
  • biomarkers and juvenile SLE
  • biomarkers and lipids
  • biomarkers and longitudinal studies
  • biomarkers and lupus nephritis
  • biomarkers and lymphocytes
  • biomarkers and macrophage activation syndrome
  • biomarkers and magnetic resonance imaging (MRI)
  • biomarkers and matrix metalloproteinase (MMP)
  • biomarkers and metabolomics
  • biomarkers and methotrexate (MTX)
  • biomarkers and microparticles
  • biomarkers and monoclonal antibodies
  • biomarkers and mycophenolate mofetil
  • Biomarkers and myositis
  • biomarkers and nephritis
  • biomarkers and neuropsychiatric disorders
  • biomarkers and neutrophils
  • Biomarkers and osteoarthritis
  • biomarkers and osteoblasts
  • biomarkers and osteoclastogenesis
  • biomarkers and outcome measures
  • biomarkers and pathogenesis
  • biomarkers and pediatric rheumatology
  • biomarkers and plasma
  • biomarkers and plasma cells
  • biomarkers and polymerase chain reaction (PCR)
  • biomarkers and polymyositis/dermatomyositis (PM/DM)
  • biomarkers and prevention
  • biomarkers and prognostic factors
  • biomarkers and proteomics
  • Biomarkers and psoriatic arthritis
  • biomarkers and pulmonary complications
  • biomarkers and radiography
  • biomarkers and registry
  • biomarkers and remission
  • biomarkers and renal disease
  • biomarkers and rheumatoid arthritis
  • biomarkers and rheumatoid arthritis (RA)
  • biomarkers and rituximab
  • biomarkers and salivary gland
  • biomarkers and salivary hypofunction
  • biomarkers and sarcoidosis
  • biomarkers and scleroderma
  • biomarkers and serologic tests
  • biomarkers and severity
  • biomarkers and spondylarthritis
  • biomarkers and spondylarthropathy
  • biomarkers and synovial cells
  • Biomarkers and systemic lupus erythematosus (SLE)
  • Biomarkers and systemic sclerosis
  • Biomarkers and takayasu arteritis
  • biomarkers and technology
  • biomarkers and therapy
  • biomarkers and thrombosis
  • biomarkers and tocilizumab
  • biomarkers and transcription factor
  • biomarkers and treatment
  • biomarkers and ultrasound
  • biomarkers and vasculitis
  • Biomechanical testing
  • Biomechanical testing and foot disorders
  • biomechanical testing and osteoarthritis
  • Biomechanics
  • Biomechanics and low back pain
  • biopsies
  • biopsies and arteriosclerosis
  • biopsies and classification criteria
  • biopsies and giant cell arteritis
  • biopsies and Hip
  • biopsies and inflammatory arthritis
  • biopsies and laboratory tests
  • biopsies and lupus nephritis
  • biopsies and prednisolone
  • biopsies and quality improvement
  • biopsies and renal
  • biopsies and salivary gland
  • biopsies and statins
  • biopsies and systemic lupus erythematosus (SLE)
  • biopsies and ultrasound
  • biopsy
  • Biosimilar
  • biosimilarity
  • biosimilarity and biosimilars
  • Biosimilarity and pharmacology
  • biosimilarity and rheumatoid arthritis (RA)
  • biosimilars
  • biosimilars and ABP 798
  • biosimilars and education
  • Biosimilars and etanercept
  • biosimilars and infliximab
  • Biosimilars and juvenile idiopathic arthritis (JIA)
  • biosimilars and patient outcomes
  • biosimilars and patient participation
  • biosimilars and pharmacokinetics
  • First |
  • « Previous Page
  • 4
  • 5
  • 6
  • 7
  • 8
  • [9]
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology